125 related articles for article (PubMed ID: 7585035)
1. Multiple sclerosis: TNF revisited, with promise.
Raine CS
Nat Med; 1995 Mar; 1(3):211-4. PubMed ID: 7585035
[No Abstract] [Full Text] [Related]
2. Type IV phosphodiesterase inhibition in experimental allergic encephalomyelitis of Lewis rats: sequential gene expression analysis of cytokines, adhesion molecules and the inducible nitric oxide synthase.
Martínez I; Puerta C; Redondo C; García-Merino A
J Neurol Sci; 1999 Mar; 164(1):13-23. PubMed ID: 10385042
[TBL] [Abstract][Full Text] [Related]
3. The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis.
Sommer N; Löschmann PA; Northoff GH; Weller M; Steinbrecher A; Steinbach JP; Lichtenfels R; Meyermann R; Riethmüller A; Fontana A
Nat Med; 1995 Mar; 1(3):244-8. PubMed ID: 7585041
[TBL] [Abstract][Full Text] [Related]
4. Preventive but not therapeutic application of Rolipram ameliorates experimental autoimmune encephalomyelitis in Lewis rats.
Jung S; Zielasek J; Köllner G; Donhauser T; Toyka K; Hartung HP
J Neuroimmunol; 1996 Aug; 68(1-2):1-11. PubMed ID: 8784254
[TBL] [Abstract][Full Text] [Related]
5. Prevention of autoimmune demyelination in non-human primates by a cAMP-specific phosphodiesterase inhibitor.
Genain CP; Roberts T; Davis RL; Nguyen MH; Uccelli A; Faulds D; Li Y; Hedgpeth J; Hauser SL
Proc Natl Acad Sci U S A; 1995 Apr; 92(8):3601-5. PubMed ID: 7536938
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic intervention in a rat model of ARDS: IV. Phosphodiesterase IV inhibition.
Turner CR; Esser KM; Wheeldon EB
Circ Shock; 1993 Mar; 39(3):237-45. PubMed ID: 8384094
[TBL] [Abstract][Full Text] [Related]
7. Beneficial effects of the phosphodiesterase inhibitors BRL 61063, pentoxifylline, and rolipram in a murine model of endotoxin shock.
Badger AM; Olivera DL; Esser KM
Circ Shock; 1994 Dec; 44(4):188-95. PubMed ID: 7628060
[TBL] [Abstract][Full Text] [Related]
8. Inhibitors of tumor necrosis factor-alpha: promising agents for the treatment of multiple sclerosis?
Hohlfeld R
Mult Scler; 1996 Jul; 1(6):376-8. PubMed ID: 9345421
[TBL] [Abstract][Full Text] [Related]
9. Brain injury and inflammation. A putative role of TNF alpha.
Arvin B; Neville LF; Barone FC; Feuerstein GZ
Ann N Y Acad Sci; 1995 Sep; 765():62-71; discussion 98-9. PubMed ID: 7486645
[No Abstract] [Full Text] [Related]
10. Ibudilast, a phosphodiesterase inhibitor, ameliorates experimental autoimmune encephalomyelitis in Dark August rats.
Fujimoto T; Sakoda S; Fujimura H; Yanagihara T
J Neuroimmunol; 1999 Mar; 95(1-2):35-42. PubMed ID: 10229113
[TBL] [Abstract][Full Text] [Related]
11. Increased peripheral benzodiazepine binding sites and pentraxin 3 expression in the spinal cord during EAE: relation to inflammatory cytokines and modulation by dexamethasone and rolipram.
Agnello D; Carvelli L; Muzio V; Villa P; Bottazzi B; Polentarutti N; Mennini T; Mantovani A; Ghezzi P
J Neuroimmunol; 2000 Sep; 109(2):105-11. PubMed ID: 10996212
[TBL] [Abstract][Full Text] [Related]
12. Characterization of cAMP-dependent inhibition of LPS-induced TNF alpha production by rolipram, a specific phosphodiesterase IV (PDE IV) inhibitor.
Prabhakar U; Lipshutz D; Bartus JO; Slivjak MJ; Smith EF; Lee JC; Esser KM
Int J Immunopharmacol; 1994 Oct; 16(10):805-16. PubMed ID: 7843852
[TBL] [Abstract][Full Text] [Related]
13. Peripheral phosphodiesterase 4 inhibition produced by 4-[2-(3,4-Bis-difluoromethoxyphenyl)-2-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-phenyl]-ethyl]-3-methylpyridine-1-oxide (L-826,141) prevents experimental autoimmune encephalomyelitis.
Moore CS; Earl N; Frenette R; Styhler A; Mancini JA; Nicholson DW; Hebb AL; Owens T; Robertson GS
J Pharmacol Exp Ther; 2006 Oct; 319(1):63-72. PubMed ID: 16809479
[TBL] [Abstract][Full Text] [Related]
14. The phosphodiesterase i.v. inhibitor rolipram in vitro reduces the numbers of MBP-reactive IFN-gamma and TNF-alpha mRNA expressing blood mononuclear cells in patients with multiple sclerosis.
Navikas V; Matusevicius D; Söderström M; Pirskanen R; Fredrikson S; Link H
Clin Neuropharmacol; 1998; 21(4):236-44. PubMed ID: 9704165
[TBL] [Abstract][Full Text] [Related]
15. Treatment with BBB022A or rolipram stabilizes the blood-brain barrier in experimental autoimmune encephalomyelitis: an additional mechanism for the therapeutic effect of type IV phosphodiesterase inhibitors.
Folcik VA; Smith T; O'Bryant S; Kawczak JA; Zhu B; Sakurai H; Kajiwara A; Staddon JM; Glabinski A; Chernosky AL; Tani M; Johnson JM; Tuohy VK; Rubin LL; Ransohoff RM
J Neuroimmunol; 1999 Jun; 97(1-2):119-28. PubMed ID: 10408965
[TBL] [Abstract][Full Text] [Related]
16. Rolipram, a specific type IV phosphodiesterase inhibitor, is a potent inhibitor of HIV-1 replication.
Angel JB; Saget BM; Walsh SP; Greten TF; Dinarello CA; Skolnik PR; Endres S
AIDS; 1995 Oct; 9(10):1137-44. PubMed ID: 8519449
[TBL] [Abstract][Full Text] [Related]
17. Rolipram, a phosphodiesterase inhibitor, in the treatment of two male patients with congenital nephrogenic diabetes insipidus.
Bichet DG; Ruel N; Arthus MF; Lonergan M
Nephron; 1990; 56(4):449-50. PubMed ID: 1964202
[No Abstract] [Full Text] [Related]
18. Suppression of acute lung injury in mice by an inhibitor of phosphodiesterase type 4.
Miotla JM; Teixeira MM; Hellewell PG
Am J Respir Cell Mol Biol; 1998 Mar; 18(3):411-20. PubMed ID: 9490659
[TBL] [Abstract][Full Text] [Related]
19. Rolipram: antidepressant used in Europe and Japan might have promise against TNF, HIV.
Smith D
AIDS Treat News; 1996 Mar; (no 242):3-4. PubMed ID: 11363192
[TBL] [Abstract][Full Text] [Related]
20. Treatment with the phosphodiesterase type-4 inhibitor rolipram fails to inhibit blood--brain barrier disruption in multiple sclerosis.
Bielekova B; Richert N; Howard T; Packer AN; Blevins G; Ohayon J; McFarland HF; Stürzebecher CS; Martin R
Mult Scler; 2009 Oct; 15(10):1206-14. PubMed ID: 19776093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
